We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $162M
1-Year Est. Return 259.04%
This Fund
S&P 500
This Quarter Est. Return
+28.52%
1 Year Est. Return
+259.04%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$162M
AUM Growth
-$31.2M
Cap. Flow
-$33.6M
Cap. Flow %
-20.7%
Top 10 Hldgs %
44.55%
Holding
71
New
15
Increased
1
Reduced
32
Closed
19

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$6.75M
2
ABVX
Abivax
ABVX
+$5.31M
3
AZN icon
AstraZeneca
AZN
+$2.27M
4
QURE icon
uniQure
QURE
+$2.12M
5
OCUL icon
Ocular Therapeutix
OCUL
+$1.65M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$5.78M
2
ELVN icon
Enliven Therapeutics
ELVN
+$5.09M
3
ELV icon
Elevance Health
ELV
+$4.3M
4
BBIO icon
BridgeBio Pharma
BBIO
+$3.44M
5
APLS
Apellis Pharmaceuticals
APLS
+$3.44M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
51
Replimune Group
REPL
$1.4B
$447K 0.28%
+40,361
New +$247K
ABUS icon
52
Arbutus Biopharma
ABUS
$1.03B
$241K 0.15%
50,166
-25,318
-34% -$111K
APLS
53
DELISTED
Apellis Pharmaceuticals
APLS
– –
-85,517
Closed -$3.44M
AVTX icon
54
Avalo Therapeutics
AVTX
$1.07B
– –
-159,341
Closed -$2.38M
CMPX icon
55
CALL
Compass Therapeutics
CMPX
$416M
– –
-25,100
Closed -$133K
CNTA
56
PUT
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-34,700
Closed -$1.38M
CYTK icon
57
PUT
Cytokinetics
CYTK
$10.6B
– –
-60,000
Closed -$3.95M
ELV icon
58
Elevance Health
ELV
$87.3B
– –
-14,677
Closed -$4.3M
FDMT icon
59
4D Molecular Therapeutics
FDMT
$836M
– –
-130,564
Closed -$1.22M
IDYA icon
60
CALL
IDEAYA Biosciences
IDYA
$3.77B
– –
-40,000
Closed -$1.33M
IDYA icon
61
PUT
IDEAYA Biosciences
IDYA
$3.77B
– –
-40,000
Closed -$1.33M
LPCN icon
62
Lipocine
LPCN
$19.4M
– –
-60,861
Closed -$486K
LQDA icon
63
PUT
Liquidia Corp
LQDA
$6.08B
– –
-40,000
Closed -$1.51M
NXTC icon
64
NextCure
NXTC
$36.2M
– –
-115,500
Closed -$1.22M
PALI icon
65
Palisade Bio
PALI
$382M
– –
-600,000
Closed -$1.05M
SLNO
66
DELISTED
Soleno Therapeutics
SLNO
– –
-61,673
Closed -$2.06M
TVTX icon
67
PUT
Travere Therapeutics
TVTX
$6.13B
– –
-20,000
Closed -$594K
WVE icon
68
PUT
Wave Life Sciences
WVE
$952M
– –
-30,000
Closed -$218K
XBI icon
69
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.4B
– –
-60,000
Closed -$7.66M
ALMS
70
PUT
Alumis Inc
ALMS
$1.42B
– –
-105,000
Closed -$2.31M
ONC
71
CALL
BeOne Medicines Ltd
ONC
$39.1B
– –
-10,000
Closed -$2.97M
1 2
3

Similar funds

STCOSD
Sageworth Trust Company of South Dakota Sioux Falls, South Dakota $162M AUM 26.79% 1-Year Est. Return
CCA
Cruiser Capital Advisors Stamford, Connecticut $162M AUM 78.28% 1-Year Est. Return
MIM
Macroview Investment Management Bethesda, Maryland $162M AUM 22.52% 1-Year Est. Return
CFG
Cornerstone Financial Group Omaha, Nebraska $162M AUM 14.64% 1-Year Est. Return
TF
TME Financial Huntington Beach, California $162M AUM 16.23% 1-Year Est. Return
CCM
Candelo Capital Management New York $162M AUM 112.87% 1-Year Est. Return
RWA
Reicon Wealth Advisors Atlanta, Georgia $162M AUM
VB
Value Base Tel Aviv, Israel $162M AUM 2.31% 1-Year Est. Return

Exome Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Exome Asset Management held 71 positions worth $162M, down 16% from $193M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Exome Asset Management withdrew a net $33.6M in Q2 2026, closing 19 positions and reducing 32 holdings. Its most notable exit was Elevance Health, an estimated $4.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 88% a quarter earlier.

Against the trend, Exome Asset Management opened a new position in TG Therapeutics worth $9.06M.

  • Exome Asset Management's largest Q2 2026 buy was TG Therapeutics: 164,915 shares worth $9.06M.
  • Exome Asset Management added most to Maze Therapeutics in Q2 2026, an estimated $686K increase.
  • Exome Asset Management's biggest Q2 2026 reduction was Praxis Precision Medicines, cutting an estimated $5.78M.
  • Exome Asset Management fully exited Elevance Health in Q2 2026, selling an estimated $4.3M.
  • Exome Asset Management's ten largest holdings make up 45% of its $162M portfolio in Q2 2026.
  • Exome Asset Management opened 15 new positions and closed 19 in Q2 2026.
  • Exome Asset Management's portfolio value fell 16% quarter-over-quarter to $162M.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.